Palisade Bio Receives Buy Rating from Brookline Capital with $16 Price Target
ByAinvest
Thursday, May 15, 2025 2:08 pm ET1min read
BRKL--
The company reported a quarterly loss of $2.23 million, with no revenue reported, matching analyst expectations. Despite the loss, Palisade Bio shares have risen by 13.0% this quarter and lost 53.4% so far this year.
Brookline Capital has given Palisade Bio a "Buy" rating with a $16.00 price target, maintaining a positive outlook on the stock's performance. The average one-year price target from three analysts is $10.67, implying an upside of 1,309.26% from the current price. The average brokerage recommendation is 1.7, indicating an "Outperform" status [2].
References:
[1] https://www.tradingview.com/news/reuters.com,2025:newsml_L8N3RL25R:0-palisade-bio-inc-reports-results-for-the-quarter-ended-march-31-earnings-summary/
[2] https://www.tradingview.com/news/reuters.com,2025:newsml_L8N3RL25R:0-palisade-bio-inc-reports-results-for-the-quarter-ended-march-31-earnings-summary/
PALI--
Palisade Bio (PALI) has received a "Buy" rating from Brookline Capital with a $16.00 price target. The analyst maintains a positive outlook on the stock's performance. Based on one-year price targets from 3 analysts, the average target price is $10.67, implying an upside of 1,309.26% from the current price. The average brokerage recommendation is 1.7, indicating "Outperform" status.
Palisade Bio Inc (PALI) reported a quarterly adjusted loss of 47 cents per share for the quarter ended March 31, 2025. This figure is higher than the same quarter last year, when the company reported EPS of $-4.59. The mean expectation of three analysts for the quarter was for a loss of 70 cents per share, with Wall Street expecting results to range from -84 cents to -48 cents per share [1].The company reported a quarterly loss of $2.23 million, with no revenue reported, matching analyst expectations. Despite the loss, Palisade Bio shares have risen by 13.0% this quarter and lost 53.4% so far this year.
Brookline Capital has given Palisade Bio a "Buy" rating with a $16.00 price target, maintaining a positive outlook on the stock's performance. The average one-year price target from three analysts is $10.67, implying an upside of 1,309.26% from the current price. The average brokerage recommendation is 1.7, indicating an "Outperform" status [2].
References:
[1] https://www.tradingview.com/news/reuters.com,2025:newsml_L8N3RL25R:0-palisade-bio-inc-reports-results-for-the-quarter-ended-march-31-earnings-summary/
[2] https://www.tradingview.com/news/reuters.com,2025:newsml_L8N3RL25R:0-palisade-bio-inc-reports-results-for-the-quarter-ended-march-31-earnings-summary/
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet